Zepbound is not covered by Medicare or many other insurance plans as a treatment for weight loss. The injectable treatment ...

Novo Nordisk (NVO) and Eli Lilly's (LLY) weight loss drugs lead Evaluate Pharma’s list of best-selling drugs projected for ...

According to BMO Capital Markets, Medicare coverage of Lilly’s Zepbound opens the door to using secondary indications to ...

Beyond the influence of new therapies on drug pricing trends, Cowen’s report also accounted for the effects of legislation ...

Popular diabetes drugs such as Ozempic and Trulicity are among 25 drugs Medicare has spent the most on but hasn't yet ...

Valo Health is eligible for a further $1.9 billion in potential milestone payments for up to nine new drug programs "Novo Nordisk, Valo Health Expand Drug Discovery and Development Pact -- Update," at ...

Novo Nordisk on Wednesday announced an expanded deal with healthtech firm Valo Health to use AI to fuel drug discovery.

A Danish team thinks it can aid rAAV manufacturers, who may not be able to spend three to five years working on a project ...

It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...

Danish drugmaker Novo Nordisk and U.S. tech firm Valo Health said on Wednesday they were expanding their 2023 agreement to ...

Variant Bio, a small biotech company based in Seattle, is using genetic information from Indigenous people to develop drugs for obesity and diabetes.